Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema

Öztürk, Bayram; Kerimoğlu, Hürkan; Bozkurt, Banu; Okudan, Süleyman

doi:10.1089/jop.2010.0195

Cited by 29 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An aliquot (200 μL) of polymer solution was added to each well of a 48-well cell culture plate. After UV sterilization and evaporation of ACN, RAW 264.7 cells were plated at the cell density of 5.0×10 4 per well. Cells were exposed to the polymer for 48 h at 37°C and 5% CO 2 .…”

Section: Mts Assaymentioning

confidence: 99%

“…Vascular endothelial growth factor (VEGF) is a naturally occurring large lipoprotein molecule, involved in various pathophysiological processes including AMD and diabetic retinopathy (DR) (3). Bevacizumab is a 149 kDa full-length recombinant humanized murine monoclonal antibody (rhumAb-anti-VEGF antibody) specific to all isoforms of VEGF (4). It specifically binds to the extracellular VEGF and blocks the angiogenic action of VEGF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery

et al. 2014

View full text Add to dashboard Cite

Abstract. The design, synthesis, and application of novel biodegradable and biocompatible pentablock (PB) copolymers, i.e., polyglycolic acid-polycaprolactone-polyethylene glycol-polycaprolactonepolyglycolic acid (PGA-PCL-PEG-PCL-PGA) and polylactic acid-polycaprolactone-polyethylene glycolpolycaprolactone-polylactic acid (PLA-PCL-PEG-PCL-PLA) for sustained protein delivery, are reported. The PB copolymers can be engineered to generate sustained delivery of protein therapeutics to the posterior segment of the eye. PB copolymers with different block arrangements and molecular weights were synthesized by ring-opening polymerization and characterized by proton nuclear magnetic resonance ( 1 H-NMR), gel permeation chromatography (GPC), and X-ray diffraction (XRD) spectroscopy. Immunoglobulin G (IgG) was selected as a model protein due to its structural similarity to bevacizumab. The influence of polymer molecular weight, composition, and isomerism on formulation parameters such as entrapment efficiency, drug loading, and in vitro release profile was delineated. Crystallinity and molecular weight of copolymers exhibited a substantial effect on formulation parameters. A secondary structure of released IgG was confirmed by circular dichroism (CD) spectroscopy. In vitro cytotoxicity, cell viability, and biocompatibility studies performed on human retinal pigment epithelial cells (ARPE-19) and/or macrophage cell line (RAW 264.7) demonstrated PB copolymers to be excellent biomaterials. Novel PB polymers may be the answer to the unmet need of a sustained release protein formulation.

show abstract

Section: Mts Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Several studies have reported good visual results for MO in BRVO with bevacizumab intravitreal therapy at 6 months and 1 year [5,6]. Bevacizumab was also reported to be as effective as ranibizumab in other diverse macular diseases [7,8,9,10]. Consequently, the latter was widely used off-label in France in BRVO treatment before February 2011.…”

Section: Introductionmentioning

confidence: 99%

Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion

et al. 2013

View full text Add to dashboard Cite

Background/Aims: To compare the efficacy of intravitreal injections of dexamethasone implants (IVD) with those of bevacizumab (IVB) for the treatment of macular oedema associated with branch retinal vein occlusion. Methods: A total of 19 patients (19 eyes) were included in this prospective pilot study. Initially, 8 eyes received three IVBs (group 1) and 11 received one IVD (group 2). All the patients underwent a 1-, 3-, 4- and 6-month follow-up visit. A repeated IVB (group 1) or IVD (group 2) was proposed at 4 months when necessary. Results: The mean visual acuity was significantly better 1 month after treatment in group 2, while the mean central macular thickness was also significantly lower in group 2. However, there was no longer any difference between the two groups at 3, 4 and 6 months, neither in terms of visual acuity nor in terms of retinal thickness. More than three IVBs were needed in 3 of 10 patients in group 1 while two IVDs were required in 10 of 11 patients in group 2. Conclusion: There was no significant difference between the two treatment regimens at the 6-month follow-up visit. A more rapid functional and anatomical efficacy was noted with IVD during the first month; however, reinjection at 4 months seemed more frequent with IVD than with IVB treatment.

show abstract

“…In Ozturk et al (21) 29 eyes were enrolled in their study in which the ranibizumab treatment increased the median BCVA from 53 to 66 ETDRS letters and decreased the median CSMT from 428 μm to 3994 a level of 279 μm after one month of injection, which was statistically significant.…”

Section: Discussionmentioning

confidence: 92%

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Eid

Hamed²,

Hudieb³

2018

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Diabetic macular edema is one of the most significant causes of blindness and severe visual impairment in patients with diabetes, which can result in reduced quality of life. Three commonly used intravitreous VEGF inhibitors aflibercept, bevacizumab and ranibizumab have been shown to be beneficial and relatively safe for the treatment of diabetic macular edema, but only aflibercept and ranibizumab are approved by the Food and Drug Administration (FDA) for this indication. Aim of the Work: To compare between the effect of ranibizumab and aflibercept in patients with diabetic macular edema as a diabetic retinopathy complication that leads to visual impairment. Patients and Methods: A prospective study of 20 patients (20 eyes) was conducted in Al-Mouneer diabetic eye center with three times injection one month apart. The patients were divided into two groups, Group A was consisted of 10 patients who received ranibizumab as 0.5 mg (0.05ml of 10mg/ml solution) an intra vitreal injection. Group B was consisted of 10 patients who received aflibercept 2 mg (0.05mL of 40mg/ml solution) as an intra vitreal injection with follow up for three months. Results: A statistically significant difference over the time through BCVA and central macular thickness with ranibizumab. There was also a statistically significant difference over the time through BCVA, central macular thickness and IOP with aflibercept. Conclusion: There was more improvement in BCVA which was significant and more reduction in central macular thickness with ranibizumab than with aflibercept. Recommendations: Larger group studies to confirm our results; longer term study for the effect of ranibizumab and aflibercept injection on the central macular thickness and IOP and comparing the effect of single injection versus multiple injections. Searching for the causes of resistance or delayed response to the intravitreal injections in some patients.

show abstract

Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema

Cited by 29 publications

References 20 publications

Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery

Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery

Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Contact Info

Product

Resources

About